Demonstrates enhanced transdermal delivery using a novel tyrosinase inhibitor, suggesting improved therapeutic applications.
This study synthesizes a novel therapeutic deep eutectic solvent (THEDES) comprising neohesperidin dihydrochalcone (NHDC) and pyruvic acid (PA) to overcome NHDC’s poor solubility and optimize its transdermal delivery as a...
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: